Tharimmune Announces $1.74 Million Public Offering

Tharimmune, Inc., a clinical-stage biotechnology firm, has announced the pricing of its registered direct public offering valued at $1.74 million. This offering includes 414,331 shares of common stock and 559,910 pre-funded warrants. Additionally, 974,241 warrants to purchase shares of common stock are being offered at an exercise price of $1.66 per share. The offering price is set at $1.786 per unit.

The capital raised is earmarked for working capital and general corporate purposes. President Street Global, LLC will act as the exclusive placement agent. The closing of this offering is anticipated around July 25, 2025, pending the requisite conditions are met.

The RD offering is facilitated under a shelf registration statement already effective since March 2023. Some securities will be available under Section 4(a)(2) of the Securities Act 1933, with future resales subject to registration.